Aalto Bio announces HBV plasma availability
This material is used in the research of potential counter measures against the virus and other conditions.
“Our industry has an unrelenting requirement for access to the most scientifically proven raw materials, a broader range of flexible controls and faster diagnostics," Aalto Bio CEO Philip Noone said. "At Aalto Bio Reagents, we are continuously expanding our product portfolio to meet this need. By bringing a comprehensive suite of HBV raw materials as well as recent raw material development for a range of recombinant Chikungunya Virus antigens and partially purified cell culture derived IgE we continue to enable our clients to bring superior best-in-class diagnostic products to market faster."
The company states that there are approximately 4 million cases of acute HBV, and roughly 1 million people are killed by chronic forms of the disease or common complications of HBV, cirrhosis of the liver and liver cancer.
The company offers a wide range of biological material used in research including antigens of pathogens, disease state blood plasma, proteins, antibodies and molecular control material.